With immediate effect, BICO's CFO, Gusten Danielsson leaves the company and his role as CFO. A recruitment process for a new CFO has begun and for the time being, the VP of Finance, Tommy Niklasson will take responsibility for BICO's finance department.
“I would like to thank Gusten Danielsson for his great contribution and commitment from BICO's start in 2016 until today. The recruitment process that has been initiated, aims to find a new CFO with solid experience of leading and organizing a finance department in listed, international groups with a simultaneous focus and drive on profitable growth.” Founder and CEO of BICO, Erik Gatenholm
For further information, please contact:
Erik Gatenholm, President and CEO of BICO Group AB
Phone (US): +1 (650) 515 5566
Phone (Sweden): +46 73-267 00 00
This information was submitted for publication, through the agency of the contact person set out above, on April 26, 2022 at 12:25 CEST.
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.
The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com